


<p><b>Name of Policy:</b> College of Medicine &amp; Life Sciences: Conflict of Interest and Disclosure (CME)</p> <p><b>Policy Number:</b> 3364-81-12-206-04</p> <p><b>Approving Officer:</b> Executive Vice President for Clinical Affairs/Dean, College of Medicine &amp; Life Sciences</p> <p><b>Responsible Agent:</b> Assistant Dean of Continuing Medical Education</p> <p><b>Scope:</b> All UT faculty, staff, students and joint sponsors</p>	 <p><b>Revision date:</b> 6/8/22</p> <p><b>Original effective date:</b> 10/1/09</p>
<p><input type="checkbox"/> New policy proposal                      <input checked="" type="checkbox"/> Minor/technical revision of existing policy</p> <p><input type="checkbox"/> Major revision of existing policy                      <input type="checkbox"/> Reaffirmation of existing policy</p>	

(A) Policy statement

Specific planning processes and organizational criteria must be followed to identify and resolve all conflicts of interest for a continuing medical education (CME) activity approved for AMA PRA Category 1 credit.

(B) Purpose of policy

To maintain compliance with the ACCME Essential Areas and Elements and to keep activities free of influence or control of a commercial entity, UT-CME requires that the content of continuing medical education activities and related materials provide balance, independence, objectivity and scientific rigor. ACCME requires that all individuals involved in the CME activity must disclose any relevant financial relationships within the past 24 (twenty four) months prior to the educational activity.

(C) Procedure

- (1) There must be complete independence from proprietary entities in the planning, designing, delivering and evaluating of AMA PRA Category 1 approved CME activities.
  - (a) All recommendations in CME activities involving clinical medicine must be based on evidence accepted within the medical profession.
  - (b) Presentations must give a balanced view of therapeutic options.
  - (c) All scientific research used to support patient care recommendations must confirm to generally accepted standards of experimental design, data collection and analysis.
  - (d) Faculty use of generic names shall contribute to therapeutic option impartiality.
  - (e) When trade names are used, those of several companies must be used rather than that of a single supporting company.

- (f) When unlabeled use of a commercial product, or an investigational use not yet approved for any purpose is discussed during an educational activity, the accredited provider shall require the speaker to disclose that the product is not labeled for the use under discussion and/or that the product is still investigational.
- (2) All individuals that have control of the content must complete a UT disclosure form with the completed AMA credit application.
- (a) Disclosure must include the name of the individual; name of the commercial interest; the nature of the relationship the person has with each commercial interest.
  - (b) For an individual with no relevant financial relationship(s) the learners must be informed that no relevant financial relationship(s) exist.
  - (c) Disclosure must be made to the learners prior to the beginning of the educational activity.
- (3) Another committee member or activity director is responsible to review disclosure forms and attest that any identified relationship does not produce a conflict of interest. Planning committees must follow the ACCME procedural flow sheet for resolving conflict of interest.

<p>/s/          Christopher J. Cooper, M.D.          Executive Vice President for Clinical Affairs and          Dean for the College of Medicine and Life          Sciences</p> <p>June 13, 2022          Date</p> <p><i>Review/Revision Completed by: CME          Advisory Committee          Assistant Dean of Continuing          Medical Education</i></p>	<p><b>Policies Superseded by This Policy:</b></p> <ul style="list-style-type: none"> <li>• <i>A-10-12-00004-0206 Guidelines for disclosure (former Health Science Campus CME policy, previously updated December 2005)</i></li> <li>• <i>A-10-12-00005-0206 Conflict of interest (former Health Science Campus CME policy, previously updated December 2005)</i></li> <li>• <i>A-10-12-00006-0206 Product Discussion and Research Reporting/Research Reporting at CME Activities (former Health Science Campus CME policy, previously updated December 2005)</i></li> </ul> <p>Initial effective date: 6/1/05</p> <p>Review/Revision Date:</p> <ul style="list-style-type: none"> <li>• 10/1/09</li> <li>• 08/06/12</li> <li>• 04/13/15</li> <li>• 09/15/15</li> <li>• 02/12/19</li> <li>• 6/8/22</li> </ul> <p>Next review date: 06/08/2025</p>
---	--